CHEPLAPHARM Arzneimittel GmbH
support_agent

Your contact persons

Archive

01/31/2020

CHEPLAPHARM buys the rights for Seroquel® and Seroquel XR® in Europe (excluding the UK) and North America

Greifswald, 01/31/2020 – AstraZeneca and CHEPLAPHARM have agreed to transfer the commercial rights for SEROQUEL® and other related brands for the North American and the European Market (excluding the…


more chevron_right
Investor Relations Archive Press releases

01/29/2020

CHEPLAPHARM’s successful institutional bond debut: 500 million euros of senior secured notes at 3.500% placed with institutional investors

CHEPLAPHARM Arzneimittel GmbH, a repeat issuer in the long-term loan market with 980 million euros of institutional term loan (“TLB”) outstanding, following its last capital market transaction in May…


more chevron_right
Investor Relations Archive

01/28/2020

CHEPLAPHARM announces pricing of Senior Secured Notes

Cheplapharm has priced €500 million aggregate principal amount of its 3.500% senior secured notes due 2027 (the “Notes”), at an offering price of 100.0%.


more chevron_right
Archive

01/23/2020

CHEPLAPHARM announces offering of Senior Secured Notes

Cheplapharm Arzneimittel GmbH has launched an offering of €400 million aggregate principal amount of senior secured notes due 2027.


more chevron_right
Archive Press releases

10/10/2019

CHEPLAPHARM strengthens its relationship with AstraZeneca by acquiring the global commercial rights to LOSEC®

AstraZeneca has agreed to sell the global commercial rights - excluding China, Japan, the U.S. and Mexico - to LOSEC® (omeprazole) and associated brands to CHEPLAPHARM. This is CHEPLAPHARM’s first…


more chevron_right
Archive

07/29/2019

Minister-President Schwesig visits CHEPLAPHARM

Schwerin/Greifswald (DE), 07/26/2019 – As part of her summer tour through Mecklenburg-Western Pomerania, Minister-President Manuela Schwesig stops by at the CHEPLAPHARM company headquarters in…


more chevron_right
Archive

06/19/2019

CHEPLAPHARM's third capital market transaction five times oversubscribed

London/Greifswald, June 13, 2019 – CHEPLAPHARM Arzneimittel GmbH very successfully closed its third capital markets transaction within just one year. Offering additional 150 million euros Term Loan B…


more chevron_right
Archive

05/10/2019

Axia Best Managed Company Award goes to CHEPLAPHARM

Düsseldorf/Greifswald (DE), May 10, 2019 – CHEPLAPHARM Arzneimittel GmbH received the "Axia Best Managed Companies Award" (Axia BMC Award) yesterday. With the award and seal of quality, the audit and…


more chevron_right
Archive

03/25/2019

CHEPLAPHARM celebrates topping-out ceremony

Just in time with the arrival of spring, CHEPLAPHARM Arzneimittel GmbH is celebrating the topping-out ceremony for the extension building at its headquarters in the Hanseatic town of Greifswald…


more chevron_right
Archive

01/09/2019

By taking over the product rights for DORMICUM® and LEXOTAN®, CHEPLAPHARM closes the very successful fiscal year 2018

more chevron_right
Back to top expand_less